FDA Approves FILSUVEZ Topical Gel for Junctional and Dystrophic EB
The U.S. Food and Drug Administration (FDA) approved FILSUVEZ (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB). Chiesi Global Rare Diseases’ FILSUVEZ is the first approved treatment for wounds associated with JEB, a rare, moderate-to-severe form of […]